Could the next generation of weight management medications include treatments given just once a month? Find out more here!

Learn more: https://drsue.ca/2025/06/will-once-a-month-weight-loss-medication-be-the-next-big-step-forward/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

I was honored to present results of CagriSema - Wegovy+Amylin (cagrilintide) - as an up-and-coming weight managment medication at the American Diabetes Association meeting yesterday, with simultaneous publication of our results in the New England Journal of Medicine. Find out more here!

Learn more: https://drsue.ca/2025/06/wegovy-plus-amylin-cagrisema-weight-management-results-revealed/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

Diabetes is a risk factor for cardiovascular (CV) disease. But could the risk of heart attack and stroke be elevated, even DECADES before the diagnosis of type 2 diabetes is made? Find out more here!

Learn more: https://drsue.ca/2025/06/could-risk-of-heart-attack-and-stroke-risk-rise-decades-before-type-2-diabetes-diagnosis/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

Could GLP1 and glucagon work together to provide weight loss benefits and improvement to metabolic and liver health? Find out about the results of the first phase 3 study of a dual GLP1/glucagon receptor agonist (mazdutide) here!

Learn more: https://drsue.ca/2025/06/mazdutide-first-phase-3-glp1-glucagon-dual-agonist-weight-management-results/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

When we as doctors think about risks of any medication, the first thing that comes to mind is the potential for side effects. But when I ask my patients what they perceive as potential risks of treatment, often the answer is something else entirely. What does a recent publication tells us about what is on people's minds?

Learn more: https://drsue.ca/2025/05/what-do-people-list-as-top-3-risks-of-weight-management-medication-and-none-of-them-are-side-effects/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

Tirzepatide, which has been approved in Canada as a diabetes medication (Mounjaro) since 2022, received Health Canada approval for weight management this week (called Zepbound). What do you need to know?

Learn more: https://drsue.ca/2025/05/zepbound-mounjaro-tirzepatide-for-weight-management-approved-in-canada/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

Zepbound/Mounjaro and Wegovy face off in a head-to-head trial. How did they compare?

Learn more: https://drsue.ca/2025/05/zepbound-mounjaro-and-wegovy-face-off/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

For a person living with obesity who has had already had a hip or knee replaced, can weight loss with obesity medication reduce the risk of needing a revisional surgery?

Learn more: https://drsue.ca/2025/04/can-weight-loss-with-obesity-medication-reduce-risk-for-revisional-surgery-after-hip-or-knee-replacement/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.